Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 1316096, 12 pages
https://doi.org/10.1155/2018/1316096
Review Article

Efficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia (ITP): A Meta-Analysis

1Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
2Beijing Hospital of Traditional Chinese Medicine, Clinical Medical College of Traditional Chinese Medicine, Capital Medical University, Beijing, China
3Department of Hematology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China

Correspondence should be addressed to Xinyi Chen; moc.621@9270iynixnehc

Received 4 June 2018; Accepted 22 October 2018; Published 12 December 2018

Academic Editor: Carlo Visco

Copyright © 2018 Jia Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. B. Cines, J. B. Bussel, H. A. Liebman, and E. T. Luning Prak, “The ITP syndrome: pathogenic and clinical diversity,” Blood, vol. 113, no. 26, pp. 6511–6521, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. B. H. Chong, J.-W. Lee, J. H. Jang et al., “International ITP Registry with Focus on the Asia Pacific Region: Update on Preliminary Findings of Epidemiological and Clinical Data,” Blood, vol. 130, 1, 2017. View at Google Scholar
  3. B. H. Chong, J.-W. Lee, J. H. Jang et al., “ITP Patients in the Asia Pacific: Are They Different?” Blood, vol. 130, 1, 2017. View at Google Scholar
  4. D. Provan, R. Stasi, A. C. Newland et al., “International consensus report on the investigation and management of primary immune thrombocytopenia,” Blood, vol. 115, no. 2, pp. 168–186, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. V. L. Patel, M. Mahévas, S. Y. Lee et al., “Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia,” Blood, vol. 119, no. 25, pp. 5989–5995, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Khellaf, A. Charles-Nelson, O. Fain et al., “Safety and efficacy of rituximab in adult immune thrombocytopenia: Results from a prospective registry including 248 patients,” Blood, vol. 124, no. 22, pp. 3228–3236, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Al-Habsi, M. Al-Khabori, M. Al-Muslahi et al., “Rituximab leads to long remissions in patients with chronic immune thrombocytopenia,” Oman Medical Journal, vol. 30, no. 2, pp. 111–114, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. Li, W. Mou, G. Lu et al., “Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia,” International Journal of Hematology, vol. 93, no. 1, pp. 91–98, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Stasi, N. Cooper, G. D. Poeta et al., “Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell depleting therapy with rituximab,” Blood, vol. 112, no. 4, pp. 1147–1150, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. X. Cui, “Effect of large dose of dexamethasone combined with rituximab on CD4+CD5+ Treg cells in patients with primary immune thrombocytopenia,” Chinese Journal of New Clinical Medicine, vol. 8, pp. 1160–1163, 2015, http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgyxwz-lnyxfc201512016. View at Google Scholar
  11. S. Gudbrandsdottir, H. S. Birgens, H. Frederiksen et al., “Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia,” Blood, vol. 121, no. 11, pp. 1976–1981, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Zaja, M. Baccarani, P. Mazza et al., “Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia,” Blood, vol. 115, no. 14, pp. 2755–2762, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Neunert, W. Lim, M. Crowther, A. Cohen, L. Solberg Jr., and M. A. Crowther, “The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia,” Blood, vol. 117, no. 16, pp. 4190–4207, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. R. B. Chen, “Clinical effect observation of glucocorticoid in combination with small dose of rituxan in treating primary immune thrombocytopenia,” Clinical Medicine, vol. 35, no. 3, pp. 6-7, 2015, http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=lcyx201503003. View at Google Scholar
  15. S. M. Chen and D.-B. Zhou, “Clinical observation of rituximab treatment of chronic primary immune thrombocytopenia in adults,” Journal of China Prescription Drug, pp. 15-16, 2015, http://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFQ&dbname=CJFDLAST2015&filename=ZGCF201510011&v=MTY5NTdXTTFGckNVUkxLZlkrUnJGaURrVkxyQVB5cklhTEc0SDlUTnI0OUVaWVI4ZVgxTHV4WVM3RGgxVDNxVHI=. View at Google Scholar
  16. Y. Chen, “Observation the Effect of Low-dose Rituximab Combined with Dexamethasone Treating Adult Persistent Immune Thrombocytopenia (ITP),” China Continuing Medical Education, vol. 7, no. 32, pp. 155-156, 2015, http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgjxyxjy201532114. View at Google Scholar
  17. L. Kaige, Conventional dose prednisone, high dose dexamethasone and high dose dexamethasone combined with low dose rituximab therapy for newly diagnosis immune thrombocytopenia. MM.Sc. Thesis, Wenzhou Medical University, 2012, http://www.wanfangdata.com.cn/details/detail.do?_type=degree&id=Y2237712.
  18. M. Jingye, L. Chan, L. Ziyi et al., “Clinical study of glucocorticoids combined with low-dose of rituximab in the treatment of refractory primary immune thrombocytopenia,” Clinical Medicine, vol. 37, no. 2, pp. 21-22, 2017, http://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFQ&dbname=CJFDLAST2017&filename=EBED201702010&v=MTcyNThNMUZyQ1VSTEtmWStSckZpRGxWN3pKSUMvT2FyRzRIOWJNclk5RVpJUjhlWDFMdXhZUzdEaDFUM3FUclc=. View at Google Scholar
  19. Z. Xiaojuan, G. Shuxia, C. Ronghua et al., “Observation of low-dose rituximab combined with dexamethasone in the treatment of adult persistent primary immune thrombocytopenia,” Shandong Medical Journal, vol. 55, no. 21, pp. 69-70, 2015 (Chinese), http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=shandyy201521030. View at Google Scholar
  20. Y. Huijuan, “Observation of rituximab combined with dexamethasone in the treatment of refractory primary immune thrombocytopenia,” Aerospace Medicine, vol. 22, no. 11, pp. 2024-2025, 2010, http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=hkhtyy201011053. View at Google Scholar
  21. M. P. Lambert and T. B. Gernsheimer, “Clinical updates in adult immune thrombocytopenia,” Blood, vol. 129, no. 21, pp. 2829–2835, 2017. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Stasi, E. Stipa, M. Masi et al., “Long-Term observation of 208 adults with chronic idiopathic thrombocytopenic purpura,” American Journal of Medicine, vol. 98, no. 5, pp. 436–442, 1995. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Ben-Yehuda, S. Gillis, and A. Eldor, “Clinical and therapeutic experience in 712 israeli patients with idiopathic thrombocytopenic purpura. Israeli ITP Study Group,” Acta Haematologica, vol. 91, no. 1, pp. 1–6, 1994. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Li, Q. Huang, C. Wang, Muhebaier, L. An, and X. Wang, “Efficacy and safety of high-dose dexamethasone combined with rhTPO for newly diagnosed adults with severe immune thrombocytopenia,” Zhonghua Xue Ye Xue Za Zhi, vol. 37, no. 2, pp. 134–137, 2016. View at Google Scholar · View at Scopus
  25. X. D. Han, J. Zhou, F. K. Yu et al., “Rituximab and Dexamethasone Combined with Cyclophosphamide for Treatment of Relapsed and Refractory Immune Thrombocytopenia,” Zhongguo Shi Yan Xue ye Xue Za Zhi, vol. 24, no. 1, pp. 162–166, 2016. View at Google Scholar
  26. D. Gómez-Almaguer, M. A. Herrera-Rojas, J. C. Jaime-Pérez et al., “Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults,” Blood, vol. 123, no. 25, pp. 3906–3908, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. J. B. Bussel, C. S. Lee, C. Seery et al., “Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration,” Haematologica, vol. 99, no. 7, pp. 1264–1271, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Godeau, R. Porcher, O. Fain et al., “Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: Results of a prospective multicenter phase 2 study,” Blood, vol. 112, no. 4, pp. 999–1004, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. V. L. Patel, M. Mahévas, R. Stasi et al., “Long-term outcome following B-cell depletion therapy with rituximab in children and adults with immune thrombocytopenia,” Blood, vol. 116, no. 21, p. 72, 2010. View at Google Scholar
  30. D. M. Arnold, F. Dentali, M. A. Crowther et al., “Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura,” Annals of Internal Medicine, vol. 146, no. 1, pp. 25–33, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Yu, S. Heck, V. Patel et al., “Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura,” Blood, vol. 112, no. 4, pp. 1325–1328, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Sakaguchi, “Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self,” Nature Immunology, vol. 6, no. 4, pp. 345–352, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Stasi, G. del Poeta, E. Stipa et al., “Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura,” Blood, vol. 110, no. 8, pp. 2924–2930, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. P. P. Sfikakis, V. L. Souliotis, K. G. Fragiadaki, H. M. Moutsopoulos, J. N. Boletis, and A. N. Theofilopoulos, “Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis,” Clinical Immunology, vol. 123, no. 1, pp. 66–73, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Bhattacharjee, D. De, S. Handa, R. W. Minz, B. Saikia, and N. Joshi, “Assessment of the Effects of Rituximab Monotherapy on Different Subsets of Circulating T-Regulatory Cells and Clinical Disease Severity in Severe Pemphigus Vulgaris,” Dermatology, vol. 232, no. 5, pp. 572–577, 2017. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Roccatello, S. Sciascia, D. Di Simone et al., “New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: a prospective study and a review of the literature,” Autoimmunity Reviews, vol. 15, no. 6, pp. 529–538, 2016. View at Publisher · View at Google Scholar · View at Scopus